Generic entry timeline

Samsca generics — when can they launch?

Samsca (TOLVAPTAN) · Otsuka · 16 active US patents · 0 expired

Earliest patent expiry
2026-09-01
expired
Full patent estate to
2030-04-07
complete protection through 2030
FDA approval
2009
Otsuka

Where Samsca sits in the generic timeline

All listed Orange Book patents for Samsca have expired. Generic entry is permitted, and ANDA filers can launch without patent infringement risk. Hatch-Waxman exclusivity (NCE/ODE/PED) may still apply if recently approved.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Composition of Matter — 8 patents
  • Formulation — 8 patents

Sample patent estate

Showing 6 of 16 active US patents. View full estate on the Samsca drug page →

  • US8501730 Composition of Matter · expires 2026-09-01
    This patent protects a process for preparing benzazepine compounds or their salts in high yield and purity on an industrial scale.
    USPTO title: Process for preparing benzazepine compounds or salts thereof
  • US8501730 Composition of Matter · expires 2026-09-01
    This patent protects a process for preparing benzazepine compounds or their salts in high yield and purity on an industrial scale.
    USPTO title: Process for preparing benzazepine compounds or salts thereof
  • US8501730 Composition of Matter · expires 2026-09-01
    This patent protects a process for preparing benzazepine compounds or their salts in high yield and purity on an industrial scale.
    USPTO title: Process for preparing benzazepine compounds or salts thereof
  • US8501730 Composition of Matter · expires 2026-09-01
    This patent protects a process for preparing benzazepine compounds or their salts in high yield and purity on an industrial scale.
    USPTO title: Process for preparing benzazepine compounds or salts thereof
  • US8501730 Composition of Matter · expires 2026-09-01
    This patent protects a process for preparing benzazepine compounds or their salts in high yield and purity on an industrial scale.
    USPTO title: Process for preparing benzazepine compounds or salts thereof
  • US8501730 Composition of Matter · expires 2026-09-01
    This patent protects a process for preparing benzazepine compounds or their salts in high yield and purity on an industrial scale.
    USPTO title: Process for preparing benzazepine compounds or salts thereof

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on Samsca — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →